S Squared Technology LLC lowered its position in AxoGen, Inc. (NASDAQ:AXGN) by 6.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 282,614 shares of the medical equipment provider’s stock after selling 20,000 shares during the quarter. AxoGen comprises approximately 4.0% of S Squared Technology LLC’s investment portfolio, making the stock its 6th biggest holding. S Squared Technology LLC owned 0.85% of AxoGen worth $4,734,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Bank of America Corp DE increased its stake in shares of AxoGen by 8.7% in the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 814 shares during the period. Parametric Portfolio Associates LLC increased its stake in shares of AxoGen by 0.9% in the first quarter. Parametric Portfolio Associates LLC now owns 10,843 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 93 shares during the period. Thompson Davis & CO. Inc. increased its stake in shares of AxoGen by 575.0% in the second quarter. Thompson Davis & CO. Inc. now owns 6,750 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 5,750 shares during the period. Campbell & CO Investment Adviser LLC increased its stake in shares of AxoGen by 3.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock valued at $116,000 after purchasing an additional 341 shares during the period. Finally, TFS Capital LLC acquired a new stake in shares of AxoGen in the first quarter valued at approximately $120,000. Institutional investors own 66.77% of the company’s stock.
AXGN has been the topic of several analyst reports. ValuEngine upgraded shares of AxoGen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Cantor Fitzgerald initiated coverage on shares of AxoGen in a research note on Thursday, June 29th. They issued an “overweight” rating and a $18.00 price target on the stock. Wedbush restated an “outperform” rating and issued a $14.00 price target (down previously from $17.00) on shares of AxoGen in a research note on Friday, May 19th. BidaskClub lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Finally, Leerink Swann initiated coverage on shares of AxoGen in a research note on Monday, July 31st. They issued an “outperform” rating and a $22.00 price target on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $15.90.
WARNING: This news story was published by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/11/s-squared-technology-llc-has-4-73-million-holdings-in-axogen-inc-axgn.html.
AxoGen, Inc. (NASDAQ AXGN) remained flat at $18.15 on Monday. 71,374 shares of the company traded hands. The firm’s market cap is $603.31 million. AxoGen, Inc. has a 52 week low of $7.65 and a 52 week high of $18.50. The stock has a 50-day moving average price of $16.09 and a 200-day moving average price of $13.78.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative net margin of 27.50% and a negative return on equity of 114.64%. The company had revenue of $15.20 million during the quarter, compared to the consensus estimate of $14.40 million. During the same period in the previous year, the firm posted ($0.09) earnings per share. The company’s revenue was up 46.2% on a year-over-year basis. On average, equities analysts forecast that AxoGen, Inc. will post ($0.31) earnings per share for the current fiscal year.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.